Eli Lilly and Company $LLY Shares Bought by Valley Brook Capital Group Inc.

Valley Brook Capital Group Inc. increased its stake in Eli Lilly and Company (NYSE:LLY) by 1.3% during the 2nd quarter, Holdings Channel.com reports. The fund owned 1,602 shares of the company’s stock after buying an additional 20 shares during the period. Eli Lilly and Company accounts for approximately 0.9% of Valley Brook Capital Group Inc.’s portfolio, making the stock its 29th largest position. Valley Brook Capital Group Inc.’s holdings in Eli Lilly and Company were worth $1,249,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the stock. Orca Investment Management LLC acquired a new stake in shares of Eli Lilly and Company in the second quarter worth approximately $1,448,000. Ackerman Capital Advisors LLC boosted its position in shares of Eli Lilly and Company by 5.8% in the second quarter. Ackerman Capital Advisors LLC now owns 272 shares of the company’s stock worth $212,000 after acquiring an additional 15 shares during the last quarter. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. acquired a new stake in shares of Eli Lilly and Company in the second quarter worth approximately $40,217,000. Means Investment CO. Inc. boosted its position in shares of Eli Lilly and Company by 4.0% in the second quarter. Means Investment CO. Inc. now owns 5,021 shares of the company’s stock worth $3,914,000 after acquiring an additional 194 shares during the last quarter. Finally, Vanguard Personalized Indexing Management LLC boosted its position in shares of Eli Lilly and Company by 11.7% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 121,020 shares of the company’s stock worth $94,420,000 after acquiring an additional 12,674 shares during the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Trading Down 2.6%

LLY opened at $833.08 on Monday. The firm has a market capitalization of $788.47 billion, a P/E ratio of 54.45, a P/E/G ratio of 1.18 and a beta of 0.47. The firm’s 50 day moving average is $742.42 and its 200-day moving average is $765.55. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $937.00. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.59 by $0.72. The company had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business’s quarterly revenue was up 37.6% on a year-over-year basis. During the same quarter last year, the firm posted $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on LLY shares. Weiss Ratings reissued a “hold (c+)” rating on shares of Eli Lilly and Company in a research report on Wednesday, October 8th. Hsbc Global Res upgraded shares of Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a report on Wednesday, August 27th. Daiwa America lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Sunday, August 17th. Deutsche Bank Aktiengesellschaft cut their price target on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating on the stock in a report on Monday, August 11th. Finally, Daiwa Capital Markets lowered shares of Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 price target on the stock. in a report on Sunday, August 17th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and ten have given a Hold rating to the company’s stock. Based on data from MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus target price of $948.06.

Insider Activity at Eli Lilly and Company

In other news, EVP Daniel Skovronsky acquired 1,000 shares of the company’s stock in a transaction dated Tuesday, August 12th. The shares were bought at an average price of $634.40 per share, for a total transaction of $634,400.00. Following the completion of the purchase, the executive vice president directly owned 137,660 shares of the company’s stock, valued at approximately $87,331,504. This trade represents a 0.73% increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO David A. Ricks purchased 1,632 shares of the company’s stock in a transaction that occurred on Tuesday, August 12th. The stock was bought at an average price of $644.77 per share, with a total value of $1,052,264.64. Following the purchase, the chief executive officer owned 546,601 shares of the company’s stock, valued at approximately $352,431,926.77. The trade was a 0.30% increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders have bought 4,514 shares of company stock valued at $2,894,841. 0.14% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.